

117TH CONGRESS  
2D SESSION

# H. R. 7308

To direct the Inspector General of the Department of Health and Human Services to investigate and report on the Vaccine Adverse Event Reporting System, and for other purposes.

---

## IN THE HOUSE OF REPRESENTATIVES

MARCH 31, 2022

Mrs. GREENE of Georgia introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

---

## A BILL

To direct the Inspector General of the Department of Health and Human Services to investigate and report on the Vaccine Adverse Event Reporting System, and for other purposes.

1       *Be it enacted by the Senate and House of Representa-  
2 tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4       This Act may be cited as the “Justice for Vaccine  
5 Victims Act of 2022”.

1   **SEC. 2. INVESTIGATION ON VACCINE ADVERSE EVENT RE-**  
2                   **PORING SYSTEM.**

3       (a) IN GENERAL.—The Inspector General of the De-  
4 partment of Health and Human Services shall investigate  
5 the Vaccine Adverse Event Reporting System of the Cen-  
6 ters for Disease Control and Prevention and Food and  
7 Drug Administration.

8       (b) REQUIRED QUESTIONS.—

9               (1) INDIVIDUALS.—

10               (A) In conducting the investigation under  
11 subsection (a), the Inspector General of the De-  
12 partment of Health and Human Services shall  
13 ask every individual who reported an adverse  
14 event to a COVID–19 vaccine at a minimum  
15 the following questions:

16               (i) Which COVID–19 vaccine did you  
17 receive?

18               (ii) Which vaccine did you receive as  
19 a booster shot?

20               (iii) Do you have any allergies or pre-  
21 existing conditions?

22               (iv) Was the adverse event mild, such  
23 as minor pain or swelling, or severe, such  
24 as leading to hospitalization, disability, or  
25 death?

- 1                         (v) Can you describe in detail the  
 2                         symptoms of the adverse event?
- 3                         (vi) In detail, can you describe any  
 4                         health problems you believe were caused by  
 5                         the adverse event?
- 6                         (vii) Are you aware of any other indi-  
 7                         viduals within your community who had a  
 8                         similar adverse event?
- 9                         (viii) When receiving a vaccination did  
 10                        you notice anything suspicious regarding  
 11                        how the vaccination was administered?
- 12                        (ix) How soon after the adverse event  
 13                        did you report it to the Vaccine Adverse  
 14                        Event Reporting System?
- 15                        (x) Did you seek compensation for the  
 16                        adverse event through the Counter-  
 17                        measures Injury Compensation Program?
- 18                        (xi) Would you be willing to testify  
 19                        under oath to a congressional committee?
- 20                        (B) If an individual described in subpara-  
 21                        graph (A) is deceased, the Inspector General of  
 22                        the Department of Health and Human Services  
 23                        shall ask one or more of the individual's imme-  
 24                        diate family members to answer (on the individ-

1           ual's behalf) the questions listed in subparagraph  
2           (A).

3           (2) MANUFACTURERS.—In conducting the investigation under subsection (a), the Inspector General of the Department of Health and Human Services shall ask each manufacturer of a COVID–19 vaccine that is distributed in the United States, at a minimum, the following questions and requests:

9           (A) What are the ingredients in your  
10          COVID–19 vaccine or vaccines distributed in  
11          the United States?

12          (B) Can you provide all information relating to your manufacturing methods and your data on the stability and safety of the product?

15          (C) What is the address of each of your locations involved in the manufacture of the vaccines?

18          (D) Did you include labeling of the vaccine or vaccines containing a specific statement describing how suspected adverse events can be reported?

22          (E) Can you provide substantive evidence you have followed all Food and Drug Administration guidance regarding product safety?

1                         (F) How many adverse events did you re-  
2                         port to the Vaccine Adverse Event Reporting  
3                         System pursuant to section 2125 of the Public  
4                         Health Service Act (42 U.S.C. 300aa-25) or  
5                         other applicable law?

6                         (G) Are you conducting your own internal  
7                         review of any adverse events caused by the vac-  
8                         cine or vaccines?

9                         (H) Are you ensuring that all public state-  
10                         ments regarding vaccine safety are accurate?

11                         (I) Are you limiting reporting data regard-  
12                         ing adverse events?

13                         (J) Would you be willing to direct rep-  
14                         resentatives to testify under oath to a congres-  
15                         sional committee?

16                         (3) HEALTH CARE PROVIDERS.—In conducting  
17                         the investigation under subsection (a), the Inspector  
18                         General of the Department of Health and Human  
19                         Services shall ask a representative sample of health  
20                         care providers, at a minimum, the following ques-  
21                         tions:

22                         (A) How many adverse events did you re-  
23                         port to the Vaccine Adverse Event Reporting  
24                         System pursuant to section 2125 of the Public

1           Health Service Act (42 U.S.C. 300aa–25) or  
2           other applicable law?

3           (B) What kind of compensation does your  
4           facility receive for vaccine administration and  
5           from which source or sources?

6           (C) Is your facility keeping a record of any  
7           increase in hospitalization rates for individuals  
8           with adverse events following vaccination?

9           (D) How many severe adverse events has  
10          your facility encountered?

11          (E) How many mild adverse events has  
12          your facility encountered?

13          (F) Has your facility determined if adverse  
14          events are caused by an immune response to  
15          the vaccine?

16          (G) Is your facility keeping a record of any  
17          problems with vaccine administration?

18          (H) Is your facility keeping a record of all  
19          breakthrough cases of COVID–19 in fully vac-  
20          cinated patients?

21          (I) Has your facility terminated any health  
22          care professionals who are opposed to vaccine  
23          mandates or who have raised questions regard-  
24          ing adverse events?

1                           (J) Would you be willing to direct rep-  
2                           resentatives of your facility to testify under  
3                           oath to a congressional committee?

4                           (c) REPORTS.—

5                           (1) REPORT ON VAERS.—

6                           (A) IN GENERAL.—Not later than 3  
7                           months after the date of enactment of this Act,  
8                           the Inspector General of the Department of  
9                           Health and Human Services shall—

10                          (i) complete the investigation under  
11                          subsection (a); and

12                          (ii) publish a report on the results of  
13                          such investigation.

14                          (B) CONTENTS.—The report under sub-  
15                          paragraph (A)(ii) shall include the following:

16                          (i) A list of all reported COVID–19  
17                          vaccine related deaths and injuries in  
18                          chronological order.

19                          (ii) Transcripts of all interviews con-  
20                          ducted by the Inspector General pursuant  
21                          to this section with an individual described  
22                          in subsection (b)(1), a manufacturer de-  
23                          scribed in subsection (b)(2), or a health  
24                          care provider described in subsection  
25                          (b)(3).

- 1                         (iii) A list of recommendations on how  
2                         the Centers for Disease Control and Pre-  
3                         vention and the Food and Drug Adminis-  
4                         tration can strengthen the Vaccine Adverse  
5                         Event Reporting System to be a more reli-  
6                         able method of obtaining information  
7                         about adverse events.
- 8                         (iv) A determination on whether the  
9                         Centers for Disease Control and Preven-  
10                         tion or the Food and Drug Administration  
11                         is hiding data regarding adverse events.
- 12                         (v) A determination on whether the  
13                         Food and Drug Administration is sup-  
14                         pressing data on the effectiveness of  
15                         monoclonal antibodies that are used to  
16                         treat COVID–19.
- 17                         (vi) Recommendations on further ac-  
18                         tions the Congress can take when con-  
19                         ducting oversight regarding data collection  
20                         by the Centers for Disease Control and  
21                         Prevention and the Food and Drug Admin-  
22                         istration.
- 23                         (vii) A determination on whether ad-  
24                         verse events are common or rare following  
25                         administration of a COVID–19 vaccine.

1                             (viii) A determination of any causal  
2                             relationship between any COVID–19 vac-  
3                             cine and specific adverse events using clin-  
4                             ical, laboratory, or epidemiologic evidence.

5                             (ix) A determination on whether ad-  
6                             verse events are intrinsic to the COVID–19  
7                             vaccine (meaning provoked by the immune  
8                             response caused by the vaccine) or related  
9                             to faulty production or administration of  
10                          the COVID–19 vaccine.

11                         (2) REPORT ON INVESTIGATION.—

12                         (A) IN GENERAL.—Not later than 6  
13                         months after publishing the report required by  
14                         paragraph (1)(A)(ii), the Inspector General of  
15                         the Department of Health and Human Services  
16                         shall submit to the relevant congressional com-  
17                         mittees a report on the implementation of this  
18                         section.

19                         (B) CONTENTS.—The report under sub-  
20                         paragraph (A) shall—

21                         (i) specify, of the amount authorized  
22                         by subsection (c)(1) to be appropriated to  
23                         carry out this section, the total amount ob-  
24                         ligated and expended; and

1                                     (ii) describe how such amount was  
2                                     used.

3                             (d) SUBPOENA POWER.—The Inspector General of  
4 the Department of Health and Human Services may, pur-  
5 suant to authorities vested in the Inspector General by  
6 other applicable law, issue subpoenas requiring the attend-  
7 ance and testimony of witnesses and the production of any  
8 evidence relating to any matter under investigation pursu-  
9 ant to this section.

10                             (e) AUTHORIZATION OF APPROPRIATIONS.—

11                             (1) IN GENERAL.—To carry out this section,  
12 there is authorized to be appropriated \$100,000,000  
13 for the period beginning on the date of enactment of  
14 this Act and ending on the date of submission of the  
15 report required by subsection (b)(2).

16                             (2) OFFSET.—

17                             (A) REPEAL OF DEDUCTION FOR CERTAIN  
18 STATE AND LOCAL, ETC., TAXES OF INDIVID-  
19 UALS.—Section 164(b)(6) of the Internal Rev-  
20 enue Code of 1986 is amended by—

21                             (i) striking “and before January 1,  
22 2026—” and all that follows through “a  
23 separate return).” and inserting “para-  
24 graphs (1), (2), and (3) of subsection (a)

1                   and paragraph (5) of this subsection shall  
2                   not apply.”; and

3                   (ii) by striking “FOR TAXABLE YEARS  
4                   2018 THROUGH 2025” in the heading there-  
5                   of.

6                   (B) EFFECTIVE DATE.—The amendments  
7                   made by this paragraph shall apply to taxable  
8                   years beginning after the date of the enactment  
9                   of this Act.

10 **SEC. 3. TERMINATION OF COVID-19 PUBLIC HEALTH EMER-**  
11                   **GENCY DECLARATION UNDER PUBLIC READI-**  
12                   **NESS AND EMERGENCY PREPAREDNESS**  
13                   **(PREP) ACT.**

14                   (a) IN GENERAL.—The Secretary of Health and  
15 Human Services shall—

16                   (1) not later than 3 months after the date of  
17                   enactment of this Act, terminate the public health  
18                   emergency declaration issued in connection with  
19                   COVID–19 pursuant to section 319F–3 of the Pub-  
20                   lic Health Service Act (42 U.S.C. 247d–6d); and

21                   (2) not reissue any such declaration or any sub-  
22                   stantially similar declaration.

23                   (b) CORRESPONDING TERMINATION OF LIABILITY  
24 PROTECTION.—No immunity from suit and liability under  
25 section 319F–3 of the Public Health Service Act (42

1 U.S.C. 247d–6d) shall apply with respect to the adminis-  
2 tration to or the use by an individual of a covered counter-  
3 measure if—

4                 (1) the immunity relies on a declaration de-  
5 scribed in subsection (a); and

6                 (2) the administration or use occurs after such  
7 declaration is terminated,

8 except that the Secretary of Health and Human Services,  
9 pursuant to section 319F–3(b)(3)(B) of such Act (42  
10 U.S.C. 247d–6d(b)(3)(B)), shall specify an additional im-  
11 munity period of 3 months for the manufacturer to ar-  
12 range for disposition of the covered countermeasure and  
13 for covered persons to take such other actions as may be  
14 appropriate to limit administration or use of the covered  
15 countermeasure, as described in clauses (i) and (ii) of such  
16 section 319F–3(b)(3)(B).

